Clinical Trial Update: Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 randomized, double-blind study of Bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Bexotegrast (PLN-74809) (bexotegrast)

Snippet

Sponsor: Pliant Therapeutics, Inc. | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: TERMINATED